Literature DB >> 15272052

RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol.

Thien P Dinh1, Satish Kathuria, Daniele Piomelli.   

Abstract

The endogenous cannabinoid 2-arachidonoylglycerol (2-AG) is produced by neurons and other cells in a stimulus-dependent manner and undergoes rapid biological inactivation through transport into cells and catalytic hydrolysis. The enzymatic pathways responsible for 2-AG degradation are only partially understood. We have shown previously that overexpression of monoacylglycerol lipase (MGL), a cytosolic serine hydrolase that cleaves 1- and 2-monoacylglycerols to fatty acid and glycerol, reduces stimulus-dependent 2-AG accumulation in primary cultures of rat brain neurons. We report here that RNA interference-mediated silencing of MGL expression greatly enhances 2-AG accumulation in HeLa cells. After stimulation with the calcium ionophore ionomycin, 2-AG levels in MGL-silenced cells were comparable with those found in cells in which 2-AG degradation had been blocked using methyl arachidonyl fluorophosphonate, a nonselective inhibitor of 2-AG hydrolysis. The results indicate that MGL plays an important role in the degradation of endogenous 2-AG in intact HeLa cells. Furthermore, immunodepletion experiments show that MGL accounts for at least 50% of the total 2-AG-hydrolyzing activity in soluble fractions of rat brain, suggesting that this enzyme also contributes to 2-AG deactivation in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272052     DOI: 10.1124/mol.104.002071

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  79 in total

Review 1.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 2.  Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors:  Ken Mackie; Nephi Stella
Journal:  AAPS J       Date:  2006-04-28       Impact factor: 4.009

Review 3.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Authors:  Regina A Mangieri; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

Review 4.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

5.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

6.  Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism.

Authors:  Jonathan Z Long; Daniel K Nomura; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2009-07-31

Review 7.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

8.  Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification.

Authors:  Nikolai Zvonok; John Williams; Meghan Johnston; Lakshmipathi Pandarinathan; David R Janero; Jing Li; Srinivasan C Krishnan; Alexandros Makriyannis
Journal:  J Proteome Res       Date:  2008-05-02       Impact factor: 4.466

9.  A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity.

Authors:  Victoria Magrioti; George Naxakis; Dimitra Hadjipavlou-Litina; Alexandros Makriyannis; George Kokotos
Journal:  Bioorg Med Chem Lett       Date:  2008-09-12       Impact factor: 2.823

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.